Fate Therapeutics presented updated clinical data for FT819, an off-the-shelf CAR T-cell therapy, showing favorable safety and meaningful responses in lupus patients without conditioning chemotherapy. Among 36 patients, 100% of extrarenal lupus patients treated without conditioning achieved clinical improvements, including remission and low disease activity states. The company also shared preclinical data on FT839, a dual-target CAR T-cell therapy for rheumatoid arthritis, demonstrating broad immune cell elimination without conditioning chemotherapy. These findings support ongoing and future trials aiming to offer safer, accessible treatments for autoimmune diseases with reduced hospital stays and treatment burdens.
Fate Therapeutics' new FT819 data on lupus patients is notable alongside today's health sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 10, 2026 17:51 WIB: of 150 priced US health-sector stocks, 76 rose and 58 fell. Notable movers include WGS (GeneDx Holdings Corp) at USD 59.50 with a 9.46% decline and 100% buy order activity, CGC (Canopy Growth Corp) at USD 0.65 up 4.37% with 79% sell orders, and ABCL (AbCellera Biologics Inc) at USD 12.86 up 2.88% with 93% sell orders.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
